Indications:
- Reducing the risk of nonsteroidal anti-inflammatory agent-induced gastric ulcer.
- Short-term treatment of active duodenal ulcer and active benign gastric ulcer.
- Maintenance therapy following healing of gastric ulcer to reduce ulcer recurrence.
- Adjunct to mifepristone for the medical termination of intrauterine pregnancy according to the “National Guideline on reproductive health care services” issued together with the Minister of Health’s Decision No. 4128 / QD-BYT dated July 29, 2016.
Dosage:
Adults:
- Preventing ulcers caused by NSAIDs:
200 mcg 4 times daily, dosage may be reduced to 100 mcg 4 times daily in patients who do not tolerate the usual dosage.
- Stomach ulcer: Short-term treatment.
100 or 200 mcg 4 times daily for 8 weeks.
- Duodenal ulcer: Short-term treatment.
100 or 200 mcg 4 times daily or 400 mcg twice daily for 4 to 8 weeks.
- Support mifepristone in abortion:
In accordance with “National Guideline on reproductive health care services” issued together with Decision No. 4128 / QD-BYT dated July 29, 2016 of the Minister of Health.
Usage:
Misoclear is administered orally. The incidence of misoprostol induced diarrhea may be minimized by using in divided doses after meals and at bedtime and by avoiding concomitantly use with a magnesium-containing or other laxative antacid..